Table 13.
Association of ABCB1 polymorphisms and drug resistance in unknown and genetic epileptic subgroups.
| Genetic | Drug-resistant patients (N = 24) | Drug-responsive patients (N = 7) | ORs | 95% CI | p value | X 2 | |||
| n | % | n | % | ||||||
| ABCB1 C1236T genotypes | TT vs. CC+CT | 14 | 58.333 | 0 | 0 | 20.714 | 1.062-404.123 | 0.046 | 7.450 |
| TT vs. CT | 14 | 70 | 0 | 0 | 24.539 | 1.175-512.647 | 0.039 | 7.950 | |
| ABCB1 G2677T genotypes | TT vs. GT | 12 | 60 | 0 | 0 | 19.118 | 0.947-386.136 | 0.054 | 6.690 |
| ABCB1 C3435T genotypes | TT vs. CC+CT | 16 | 66.667 | 1 | 14.286 | 12.000 | 1.226-117.417 | 0.033 | 6 |
| TT vs. CT | 16 | 100 | 1 | 20 | 99.000 | 3.418-2867.633 | 0.008 | 15.810 | |
| ABCB1 C1236T alleles | T vs. C | 33 | 68.750 | 5 | 35.714 | 3.960 | 1.132-13.850 | 0.031 | 4.990 |
|
| |||||||||
| Unknown | Drug-resistant patients (N = 26) | Drug-responsive patients (N = 31) | ORs | 95% CI | p value | X 2 | |||
| n | % | n | % | ||||||
| ABCB1 G2677T genotypes | GG vs. GT+TT | 6 | 23.077 | 1 | 3.226 | 9.000 | 1.006-80.525 | 0.049 | 5.170 |
| TT vs. GG+GT | 15 | 57.692 | 5 | 16.129 | 7.091 | 2.066-24.344 | 0.002 | 10.730 | |
| ABCB1 C3435T genotypes | TT vs. CC | 14 | 82.353 | 3 | 16.667 | 23.333 | 4.021-135.391 | ≤0.001 | 15.100 |
| ABCB1 C3435T alleles | T vs. C | 37 | 71.154 | 19 | 30.645 | 5.583 | 2.491-12.513 | ≤0.001 | 18.570 |
| ABCB1 C1236T-G2677T | TT | 6 | 23.077 | 1 | 3.226 | 9.000 | 1.006-80.525 | 0.049 | 5.170 |
| ABCB1 G2677T-C3435T | TT | 6 | 23.077 | 0 | 0 | 19.976 | 1.067-374.011 | 0.045 | 8 |
| ABCB1 C1236T-C3435T | CT | 8 | 30.769 | 2 | 6.452 | 6.444 | 1.229-33.805 | 0.028 | 5.780 |
| TT | 6 | 23.077 | 1 | 3.226 | 9.000 | 1.006-80.525 | 0.049 | 5.170 | |
Values (n and %). ORs: odds ratio; 95% CI: confidence interval; significant p value ≤ 0.05; X2: chi-square.